Second-Line Antiretroviral Treatment Outcome in HIV-Infected Patients Coinfected with Tuberculosis in Pakistan

Figure 1

Virological and immunological outcome in TB coinfection and ATT coadministration in HIV patients on 2^nd line of treatment. HIV^posTB^pos: HIV- and TB-coinfected patient group; ART^yesATT^yes: antiretroviral therapy and antitubercle therapy-coadministered patient group; ART^yesATT^no: only antiretroviral therapy-administered patient group. A1: describes percentage of HIV^posTB^pos and HIV^posTB^neg patients on follow-up for a period of nine years with 6-month gap in between. Numbers shown in bars are number of patients. A2: describes percentage of patients on ART^yesATT^yes and ART^yesATT^no follow-up for a period of nine years with 6-month gap in between. Numbers shown in bars are number of patients. B1: CD count (cell/mm³) of HIV^posTB^pos and HIV^posTB^neg patients during period of study. B2: CD count (cell/mm³) of patients on ART^yesATT^yes and ART^yesATT^no during period of study. C1: viral load (log₁₀ copies per ml) of HIV^posTB^pos and HIV^posTB^neg patients during period of study. C2: viral load (log₁₀ copies per ml) of patients on ART^yesATT^yes and ART^yesATT^no during period of study. D1: CD4 gain (cell/mm³) of HIV^posTB^pos and HIV^posTB^neg patients during period of study. D2: CD4 gain (cell/mm³) of patients on ART^yesATT^yes and ART^yesATT^no during period of study.